Lunai Bioworks (LNAI) vs Propanc Biopharma (PPCB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lunai Bioworks is the larger company by market cap ($5.1 million vs $4.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | LNAI | PPCB |
|---|---|---|
| Share price | $1.12 | $0.471 |
| Market cap | $5.08M | $4.63M |
| 1-day change | +2.75% | -5.55% |
| EPS (TTM) | $-61.36 | $-17.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.28 | $48.75 |
| 52-week low | $1.08 | $0.46 |
| Distance from 52-week high | -91.57% | -99.03% |
| Average volume | 181.37K | 1.79M |
| Shares outstanding | 4.53M | 9.83M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
LNAI vs PPCB FAQ
Which is bigger, Lunai Bioworks or Propanc Biopharma?
Lunai Bioworks (LNAI) is larger, with a market capitalization of $5.08M compared with $4.63M for Propanc Biopharma (PPCB).
Are Lunai Bioworks and Propanc Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.